Organon Arixtra Anti-Thrombotic Could Clear FDA By Mid-August
Executive Summary
Organon's anti-thrombotic agent Arixtra could receive approval from FDA in mid-August, Organon President Hans Vemer told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.
You may also be interested in...
Sanofi Steps Up Avapro Support While Bristol Awaits Vanlev And DuPont
Sanofi-Synthelabo is increasing its role in the co-promotion of Avapro ahead of Bristol-Myers Squibb's resubmission of the NDA for Vanlev.
Sanofi Prepares Pentasaccharide NDA For Nov. Following Favorable Phase III
Patients treated with Sanofi-Synthelabo/Organon's pentasaccharide compound SR 90107 have 50% fewer venous thromboembolic events than those on enoxaparin (Aventis' Lovenox), Sanofi-Synthelabo reported at a meeting with the financial community in London Sept. 6.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011